These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 19050794)
21. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088 [TBL] [Abstract][Full Text] [Related]
23. Assessment of microvessel density in core needle biopsy specimen in breast cancer. Rydén L; Boiesen P; Jönsson PE Anticancer Res; 2004; 24(1):371-5. PubMed ID: 15015623 [TBL] [Abstract][Full Text] [Related]
24. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111 [TBL] [Abstract][Full Text] [Related]
25. [HER2/neu expression in Venezuelan patients with locally advanced breast cancer]. Morales L; Reigosa A; Caleiras E; Mora R; Marrero N; Payares E; Molina K; Sucre L Invest Clin; 2008 Mar; 49(1):69-78. PubMed ID: 18524333 [TBL] [Abstract][Full Text] [Related]
26. Obesity and risk of the less commonly diagnosed subtypes of breast cancer. Stark A; Schultz D; Kapke A; Nadkarni P; Burke M; Linden M; Raju U Eur J Surg Oncol; 2009 Sep; 35(9):928-35. PubMed ID: 19121564 [TBL] [Abstract][Full Text] [Related]
27. [A study on the relationship between breast cancer molecular classification and prognosis]. Chen XS; Ma CD; Chen CM Zhonghua Wai Ke Za Zhi; 2008 Sep; 46(18):1400-3. PubMed ID: 19094512 [TBL] [Abstract][Full Text] [Related]
28. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627 [TBL] [Abstract][Full Text] [Related]
29. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077 [TBL] [Abstract][Full Text] [Related]
30. Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer. Glynn RW; Miller N; Mahon S; Kerin MJ Oncol Rep; 2012 Jul; 28(1):365-9. PubMed ID: 22552811 [TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of microvessel density in breast cancer of Thai women. Kanjanapanjapol S; Wongwaisayawan S; Phuwapraisirisan S; Wilasrusmee C J Med Assoc Thai; 2007 Feb; 90(2):282-90. PubMed ID: 17375633 [TBL] [Abstract][Full Text] [Related]
32. Analysis of the cellular centrosome in fine-needle aspirations of the breast. Guo HQ; Gao M; Ma J; Xiao T; Zhao LL; Gao Y; Pan QJ Breast Cancer Res; 2007; 9(4):R48. PubMed ID: 17662154 [TBL] [Abstract][Full Text] [Related]
33. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels. Gravina GL; Festuccia C; Millimaggi D; Tombolini V; Dolo V; Vicentini C; Bologna M Urology; 2009 Aug; 74(2):452-7. PubMed ID: 19285710 [TBL] [Abstract][Full Text] [Related]
34. Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002-2004 . Zarcone M; Amodio R; Campisi I; Cusimano R; Dolcemascolo C; Miceli V; Traina A; Macaluso M Ann N Y Acad Sci; 2009 Feb; 1155():222-6. PubMed ID: 19250207 [TBL] [Abstract][Full Text] [Related]
35. Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. Ensinger C; Prommegger R; Kendler D; Gabriel M; Spizzo G; Mikuz G; Kremser R Anticancer Res; 2003; 23(3B):2349-53. PubMed ID: 12894514 [TBL] [Abstract][Full Text] [Related]
36. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression. Kaya H; Bozkurt SU; Erbarut I; Djamgoz MB Pathol Res Pract; 2008; 204(6):367-71. PubMed ID: 18342452 [TBL] [Abstract][Full Text] [Related]
37. Proposed prognostic score for breast carcinoma on fine needle aspiration based on nuclear grade, cellular dyscohesion and bare atypical nuclei. Fan F; Namiq AL; Tawfik OW; Thomas PA Diagn Cytopathol; 2006 Aug; 34(8):542-6. PubMed ID: 16850493 [TBL] [Abstract][Full Text] [Related]
38. C-erbB-2: expression in patients with breast carcinoma in comparison to patients with benign breast diseases. Kalogeraki A; Tzardi M; Datseris G; Kanavaros P; Karvelas C; Chalkiadakis G; Tsiftsis D; Delides G Anticancer Res; 1996; 16(2):765-71. PubMed ID: 8687126 [TBL] [Abstract][Full Text] [Related]
39. HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. Lesnikova I; Lidang M; Hamilton-Dutoit S; Koch J APMIS; 2009 Oct; 117(10):737-45. PubMed ID: 19775342 [TBL] [Abstract][Full Text] [Related]
40. A distinct microvascular pattern accompanied by aggressive clinical course in breast carcinomas: a fact or a coincidence? Safali M; Karslioğlu Y; Arpaci F; Kurt B; Günhan O Pathol Res Pract; 2010 Feb; 206(2):93-7. PubMed ID: 19945801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]